Your browser doesn't support javascript.
loading
Multifaceted roles of PD-1 in tumorigenesis: From immune checkpoint to tumor cell-intrinsic function.
Chen, Huiqing; Wei, Jiayu; Zhu, Zhen; Hou, Yongzhong.
Afiliação
  • Chen H; School of Life Sciences, Jiangsu University, Zhenjiang, China.
  • Wei J; School of Life Sciences, Jiangsu University, Zhenjiang, China.
  • Zhu Z; Zhenjiang Stomatological Hospital, Zhenjiang, China.
  • Hou Y; School of Life Sciences, Jiangsu University, Zhenjiang, China.
Mol Carcinog ; 63(8): 1436-1448, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38751009
ABSTRACT
Programmed cell death 1 (PD-1), a key immune checkpoint receptor, has been extensively studied for its role in regulating immune responses in cancer. However, recent research has unveiled a complex and dual role for PD-1 in tumorigenesis. While PD-1 is traditionally associated with immune cells, this article explores its expression in various cancer cells and its impact on cancer progression. PD-1's functions extend beyond immune regulation, as it has been found to both promote and suppress tumor growth, depending on the cancer type. These findings have significant implications for the future of cancer treatment and our understanding of the immune response in the context of cancer. This article calls for further research into the multifaceted roles of PD-1 to optimize its therapeutic potential and improve patient outcomes in the fight against cancer.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor de Morte Celular Programada 1 / Carcinogênese / Neoplasias Limite: Animals / Humans Idioma: En Revista: Mol Carcinog Assunto da revista: BIOLOGIA MOLECULAR / NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor de Morte Celular Programada 1 / Carcinogênese / Neoplasias Limite: Animals / Humans Idioma: En Revista: Mol Carcinog Assunto da revista: BIOLOGIA MOLECULAR / NEOPLASIAS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China